Big Pharma Boasts of 117 Lymphoma Treatments in Pipeline

According to the details of a report released by the Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical industry in the United States has nearly one thousand drugs, medicines and vaccines under clinical trials or under review by the US Food & Drug Administration, including 117 directed at the many subtypes of Hodgkin's and non-Hodgkin's lymphoma.

“Despite amazing strides in the ongoing battle against cancer, the many forms of this disease remain a major public health challenge for patients, their families, healthcare providers. Additionally, cancer is a burden on economies in the United States and throughout the world,” PhRMA President and CEO John J. Castellani is quoted as saying. “The ceaseless efforts of biopharmaceutical researchers in America have brought new and improved treatment to patients, providing options that didn't exist before. This report reflects stories of remarkable science, individual perseverance and an unwavering commitment to patients.”

The benefits of all this research can be seen in cancer survivorship, says PhRMA, citing statistics from the American Cancer Society that point to a reduction in cancer death rates between 1990 and 2007, notably a 22% drop for men and 14% for women. In total, almost 900,000 fewer people have died from cancer in that time.

The full free report can be accessed here (opens as PDF document): Medicines In Development For Cancer 2012.

Source: Therapeutics Daily